Oaktree Acquisition CORP Iii Life Sciences 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
Oaktree Acquisition Corp. III has postponed its general meeting to October 23, 2026, to allow for further proxy solicitation and voting.
NASDAQ
Oaktree Acquisition Corp. III Life Sciences reports preliminary redemption results, with over 13.3 million Class A ordinary shares tendered for redemption.
NASDAQ
Oaktree Acquisition Corp. III Life Sciences announced the resignation of its CFO, Thomas Sweeney, and the immediate appointment of George A. Martinez as his successor.
NASDAQ
Oaktree Acquisition Corp. III Life Sciences announced the appointment of Dr. David A. Berry, a seasoned life sciences executive, as an independent director to its board.
NASDAQ
Oaktree Acquisition Corp. III Life Sciences announced the resignation of CFO Courtney Conigliaro and the immediate appointment of Thomas Sweeney, a seasoned financial executive from Oaktree Capital Management, as her successor.
NASDAQ
Oaktree Acquisition Corp. III Life Sciences reports the resignation of a director and the appointment of a new chairman and director.
NASDAQ
Oaktree Acquisition Corp. III Life Sciences will allow separate trading of its Class A ordinary shares and warrants starting December 16, 2024.
NASDAQ
Oaktree Acquisition Corp. III Life Sciences has partially exercised its over-allotment option, resulting in additional gross proceeds of $17.3 million and the forfeiture of some Class B shares.
NASDAQ
Oaktree Acquisition Corp. III Life Sciences successfully completed its initial public offering (IPO) and a concurrent private placement, raising a total of $175 million which is held in trust for a future business combination.
NASDAQ
Oaktree Acquisition Corp. III Life Sciences has successfully priced its initial public offering of 17.5 million units at $10.00 per unit, raising gross proceeds of $175 million.